Understand the source comparison
IGF-1 LR3 Review 2026: Research Compound Comparison
Laboratory-grade IGF-1 analogs and related growth factor peptides serve distinct experimental purposes based on receptor selectivity, half-life, and binding protein interactions. Selecting the appropriate peptide depends on whether the research question requir
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Laboratory-grade IGF-1 analogs and related growth factor peptides serve distinct experimental purposes based on receptor selectivity, half-life, and binding protein interactions. Selecting the appropriate peptide depends on whether the research question requires sustained receptor activation, IGFBP evasion, or specific downstream pathway engagement.
- IGF-1 LR3
- IGF-1R
- 20–30 hours
- ~10% of native IGF-1
- Sustained IGF-1R activation in serum-containing systems; myogenesis, adipogenesis, metabolic studies
- Best choice for multi-day protocols requiring consistent bioavailability without IGFBP interference
- Native IGF-1
- 10–12 minutes
- High (>80% bound to IGFBP-3)
- Acute receptor activation studies, serum-free systems, IGFBP interaction research
- Appropriate for short-term signaling studies or when IGFBP interactions are part of the experimental model
- Ipamorelin
- GHSR-1a (growth hormone secretagogue receptor)
- 2 hours
- None (GHS, not IGF analog)
- Growth hormone release studies, indirect IGF-1 upregulation via GH axis
- Indirect IGF-1 elevation; used when studying GH-mediated IGF-1 production rather than direct receptor activation
- MK 677
- GHSR-1a
- 4–6 hours (oral bioavailability)
- Prolonged GH secretion studies, IGF-1 upregulation over days to weeks
- Non-peptide GHS with oral activity; models chronic GH/IGF-1 elevation but lacks direct IGF-1R engagement
- Des(1-3)IGF-1
- 2–4 hours
- ~1% of native IGF-1 (even lower than LR3)
- High-potency, localized receptor activation; autocrine signaling models
- More potent than IGF-1 LR3 due to near-zero IGFBP binding, but shorter half-life limits practical use
- IGF-1 LR3 occupies a unique position among IGF-1 analogs. It combines multi-hour bioavailability with near-complete IGFBP evasion, making it the standard choice for extended cell culture protocols where continuous receptor stimulation is required. Native IGF-1 remains essential for experiments examining IGFBP regulatory mechanisms or acute signaling dynamics, while growth hormone secretagogues like Ipamorelin and MK 677 are used to model endogenous IGF-1 upregulation through GH release rather than direct receptor activation. Des(1-3)IGF-1, though more potent, sees limited use due to its short half-life and synthesis cost. IGF-1 LR3 delivers most of the IGFBP-evasion benefit with far greater stability.